Laying the Foundations for Long-Term Remission in High-Risk* Acute Myeloid Leukaemia (AML)

Back to resources

Dr Donal McLornan presents a case study in the context of the 5-year data for Vyxeos Liposomal.1

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data

FOOTNOTES

*High-risk AML is defined as therapy-related AML or AML with myelodysplasia-related changes.

ABBREVIATIONS

AML, acute myeloid leukaemia.

REFERENCES:
  1. Lancet JE, et al. E-poster EP556. EHA25 Virtual Congress 2020

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100027 | March 2021